CoChat

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

Open access

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In a cross-sectional study we studied the fasting serum DPP-4 enzymatic activity (sDPP-4) and the insulin resistance index (HOMA2-IR) in gliptin naïve patients with type 2 diabetes and in non-alcoholic fatty liver disease (NAFLD) and in healthy controls (CNTRL). METHODS AND FINDINGS: sDPP-4 was measured by kinetic assay in 39 NAFLD (F/M:19/20, mean age: 47.42 yrs) and 82 type 2 diabetes (F/M:48/34, 62.8 yrs) patients and 26 (F/M:14/12, 35.3 yrs) controls. Definition of T2D group as patients with type 2 diabetes but without clinically obvious liver disease created non-overlapping study groups. Diagnosis of NAFLD was based on ultrasonography and the exclusion of other etiololgy. Patients in T2D and NAFLD groups were similarly obese. 75 g CH OGTT in 39 NAFLD patients: 24-NGT, 4-IGT or IFG ("prediabetes"), 11-type 2 diabetes. HOMA2-IR: CNTRL: 1.44; T2D-group: 2.62 (p = 0.046 vs CNTRL, parametric tests); NAFLD(NGTonly): 3.23 (p = 0.0013 vs CNTRL); NAFLD(IFG/IGT/type 2 diabetes): 3.82 (p<0.001 vs CNTRL, p = 0.049 vs 2TD group). sDPP-4 activity was higher in NAFLD both with NGT (mean:33.08U/L) and abnormal glucose metabolism (30.38U/L) than in CNTRL (25.89U/L, p<0.001 and p = 0.013) or in T2D groups (23.97U/L, p<0.001 and p = 0.004). Correlations in NAFLD among sDPP-4 and ALT: r = 0.4637,p = 0.0038 and gammaGT: r = 0.4991,p = 0.0017 and HOMA2-IR: r = 0.5295,p = 0.0026 and among HOMA2-IR and ALT: r = 0.4340,p = 0.0147 and gammaGT: r = 0.4128,p = 0.0210. CONCLUSIONS: The fasting serum DPP-4 activity was not increased in T2D provided that patients with liver disease were intentionally excluded. The high serum DPP-4 activities in NAFLD were correlated with liver tests but not with the fasting plasma glucose or HbA1C supporting that the excess is of hepatic origin and it might contribute to the speedup of metabolic deterioration. The correlation among gammaGT, ALT and serum DPP-4 activity and also between serum DPP-4 activity and HOMA2-IR in NAFLD strongly suggests that serum DPP-4 activity should be considered as a novel liver disease biomarker.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0012226

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fasting serum DPP-4 enzymatic activities in patients with type 2 diabetes without clinically diagnosed liver disease (2TD group); in NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).
Figure 1 Fasting serum DPP-4 enzymatic activities in patients with type 2 diabetes without clinically diagnosed liver disease (2TD group); in NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).CC BY · PubMed Central
Figure 2 HOMA2-Insulin resistance index in patients with type 2 diabetes without clinically diagnosed liver disease (2TD group), in NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).
Figure 2 HOMA2-Insulin resistance index in patients with type 2 diabetes without clinically diagnosed liver disease (2TD group), in NAFLD patients with normal and abnormal glucose metabolism and in healthy controls (CNTRL group).CC BY · PubMed Central
Figure 3 Significant correlation (r = 0.4087; p = 0.0120) between the liver disease biomarker ALT and the fasting serum DPP-4 enzymatic activity after logarithmic transformation in NAFLD patients.
Figure 3 Significant correlation (r = 0.4087; p = 0.0120) between the liver disease biomarker ALT and the fasting serum DPP-4 enzymatic activity after logarithmic transformation in NAFLD patients.CC BY · PubMed Central
Figure 4 Significant correlation (r = 0.3827; p = 0.019) between the liver disease biomarker γGT and the fasting serum DPP-4 enzymatic activity after logarithmic transformation in NAFLD patients.
Figure 4 Significant correlation (r = 0.3827; p = 0.019) between the liver disease biomarker γGT and the fasting serum DPP-4 enzymatic activity after logarithmic transformation in NAFLD patients.CC BY · PubMed Central
Figure 5 Significant correlation (r = 0.5295; p = 0.0026) between the HOMA2-Insulin resistance index and the fasting serum DPP-4 enzymatic activity in NAFLD patients.
Figure 5 Significant correlation (r = 0.5295; p = 0.0026) between the HOMA2-Insulin resistance index and the fasting serum DPP-4 enzymatic activity in NAFLD patients.CC BY · PubMed Central
Figure 6 ROCurve for Multiple Logistic Regression (Equation = 0.7049−0.023*(Fasting Plasma Glucose)+0.0188*(HOMA2-IR)−0.084*(HbA1c)+0.0092*(sDPP−4)+0.004*(ASAT)+0.0000072*(ALAT)+0.0004*(gGT)−0.2859*(ASAT/ALAT)+0.0819*(TG). Criterion 0.3712, below: T2D, above: NAFLD).
Figure 6 ROCurve for Multiple Logistic Regression (Equation = 0.7049−0.023*(Fasting Plasma Glucose)+0.0188*(HOMA2-IR)−0.084*(HbA1c)+0.0092*(sDPP−4)+0.004*(ASAT)+0.0000072*(ALAT)+0.0004*(gGT)−0.2859*(ASAT/ALAT)+0.0819*(TG). Criterion 0.3712, below: T2D, above: NAFLD).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 121

Metadata

Authors
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A.
Affiliations
Semmelweis University (HU)
Corresponding author
Firneisz, Gábor
Venue
PLoS ONE
Published
2010-08-18
Volume
5
Issue
8
Pages
e12226
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2012528744
Cited by
121
References
25
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 4 · 2018: 11 · 2017: 15 · 2016: 15 · 2015: 12 · 2014: 12 · 2013: 8 · 2012: 3
FWCI
4.20
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Semmelweis University Repository (Semmelweis University) (submittedVersion)
Funders
  • Magyar Diabetes Társaság
  • Hungarian Scientific Research Fund
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
dipeptidyl peptidase IV, non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, HOMA-IR, liver disease biomarkers, alanine aminotransferase, gamma-glutamyl transferase, prediabetes, insulin resistance index, hepatic steatosis, liver fibrosis
MeSH terms
Adult, Aged, Diabetes Mellitus, Type 2, Fasting, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Middle Aged, Obesity, Biomarkers, Logistic Models, Case-Control Studies, Dipeptidyl Peptidase 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker. https://app.cochat.ai/papers/10.1371/journal.pone.0012226
The paper
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010). Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker. PLoS ONE. https://doi.org/10.1371/journal.pone.0012226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.